Home Cart Sign in  
Chemical Structure| 57396-78-8 Chemical Structure| 57396-78-8

Structure of Oroxin A
CAS No.: 57396-78-8

Chemical Structure| 57396-78-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE), activates peroxisome proliferator-activated receptor γ (PPARγ) by docking into the PPARγ protein ligand-binding domain. Oroxin A exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.

Synonyms: Baicalein-7-O-Glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oroxin A

CAS No. :57396-78-8
Formula : C21H20O10
M.W : 432.38
SMILES Code : O=C1C=C(C2=CC=CC=C2)OC3=C1C(O)=C(O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C3
Synonyms :
Baicalein-7-O-Glucoside
MDL No. :MFCD22125001
InChI Key :IPQKDIRUZHOIOM-IAAKTDFRSA-N
Pubchem ID :5320313

Safety of Oroxin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT22 cells 5 µM 48 h To evaluate the protective effect of Oroxin A on neuronal damage in the SAH model. Results showed that Oroxin A significantly alleviated hemin-induced neuronal injury and inhibited ferroptosis. PMC11069275
HepG2 cells 5 μM or 50 μM 24 h Oroxin A reduced lipid accumulation in oleic acid-induced HepG2 cells, decreased cellular TG and TC levels, and inhibited the transcriptional activity of SREBP1 and SREBP2. PMC11015455
HT22 cells 5 µM 48 h To evaluate the neuroprotective effects of Oroxin A on HT22 cells in the SAH model. Results showed that Oroxin A significantly alleviated hemin-induced neuronal injury and inhibited ferroptosis. PMC11069275

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Subarachnoid hemorrhage (SAH) model Tail vein injection 5 mg/kg Single dose, observed for 48 hours To evaluate the protective effect of Oroxin A on early brain injury after SAH. Results showed that Oroxin A significantly improved survival rates, neurological functions, mitigated neuronal death and brain edema, and attenuated the inflammatory response. PMC11069275
Sprague-Dawley rats High-fat diet-induced lipid metabolism disorder model Oral gavage 50 mg/kg or 200 mg/kg Once daily for 3 months Oroxin A improved disordered lipid metabolism in high-fat diet-fed non-insulin-resistant rats, reduced plasma and hepatic lipid levels, and enhanced the lipid-lowering effect of atorvastatin. PMC11015455
C57BL/6 mice Subarachnoid hemorrhage (SAH) model Tail vein injection 5 mg/kg Single dose, observed for 48 hours To evaluate the neuroprotective effects of Oroxin A in the SAH model. Results showed that Oroxin A significantly improved survival rates, enhanced neurological functions, mitigated neuronal death and brain edema, and attenuated the inflammatory response. PMC11069275

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.13mL

4.63mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories